TY - JOUR
T1 - Mpox
T2 - Characterization and clinical outcomes of patients in Colombian healthcare institutions
AU - Álvarez-Moreno, Carlos Arturo
AU - Reveiz, Ludovic
AU - Aristizabal, Claudia
AU - Quevedo, Jesús
AU - Rubio, María Lucia Mesa
AU - Arévalo-Mora, Leonardo
AU - Villamil, Julián Felipe Porras
AU - Padilla, Monica
AU - Alzate-Angel, Juan Carlos
AU - Rylance, Jamie
AU - Firdavs, Kurbonov
AU - de la Hoz, Ilich
AU - Valderrama-Beltran, Sandra Liliana
AU - Arboleda, Santiago
AU - Sussmann, Otto
AU - Andrade, Javier
AU - Velásquez, Carolina Murillo
AU - García, Estefania
AU - Galindo, Ximena
AU - Martínez, Daniela
AU - Arango, Lisandra
AU - Martínez, Ernesto
AU - Reyes-Caicedo, Karyna
AU - Suarez, Mónica Mantilla
AU - Ríos, Juana Gutiérrez
AU - Garay, Alexandra
AU - Pinzón, Wendy
AU - Crispin, Ana María
AU - Chaillon, Antoine
N1 - © 2025 Published by Elsevier Inc.
PY - 2025/3/15
Y1 - 2025/3/15
N2 - Introduction: In 2022, the world experienced a monkeypox outbreak caused by the Clade IIb strain of the virus. While this outbreak had widespread effects, more information is needed on mpox's specific impact in Colombia, particularly regarding how it is managed, its burden, and its epidemiology. This research seeks to examine the medical context, clinical presentation, and health outcomes of individuals diagnosed with mpox infection, with a particular focus on those with HIV in Colombia. Methods: This retrospective study was conducted in fourteen Health institutions in Colombia based on computerized clinical records from Jan 2022 to Dec 2023. Clinical and epidemiological characteristics were collected from diagnosis until discharge (or death). Participants in the study were diagnosed through molecular methods (PCR) and their clinical evolution was tracked through hospital and/or outpatient medical records. Registered variables were based on the mpox 2023 Case Report Form (2023 - CRF) proposed by the World Health Organization. Results: One thousand four hundred thirteen (1413, 97.2 % male) individuals, including 2.6 % identified as healthcare workers, were included in this study. The majority (54 %, 764/1413 individuals) were persons living with HIV (PWH) and almost one-third of them (30.1 %, n = 284) of participants had concomitant sexually transmitted diseases and HIV, with syphilis being the most prevalent (20.4 %), followed by Neisseria gonorrhoeae (16.4 %). Complications were infrequent, with cellulitis being the most common, and no individuals received mpox-specific treatment or vaccination. Although all individuals had skin lesions distributed across various body regions, differences were noted in lesion distribution among women. Those living with HIV showed higher emergency department attendance and reported having known mpox contacts. While complications were rare, with cellulitis being the most common, women living with HIV showed a higher rate of emergency room visits and known mpox contacts. Although not statistically significant, gastrointestinal, musculoskeletal, psychological, respiratory, and STI symptoms, including syphilis and urethritis, were more common in the virologically non-suppressed HIV group. At the same time, proctitis was more prevalent in the suppressed group. No significant differences were found based on CD4 count, using 200 cells/mm3 in PWH. Conclusion: Over half of the participants were people living with HIV (PWH), with a significant presence of STIs like syphilis. While skin lesions and complications varied, no significant differences were linked to CD4 count or viral load suppression. Mpox symptomatology was not significantly associated with unsuppressed viral loads or low CD4 levels, highlighting the need for further research.
AB - Introduction: In 2022, the world experienced a monkeypox outbreak caused by the Clade IIb strain of the virus. While this outbreak had widespread effects, more information is needed on mpox's specific impact in Colombia, particularly regarding how it is managed, its burden, and its epidemiology. This research seeks to examine the medical context, clinical presentation, and health outcomes of individuals diagnosed with mpox infection, with a particular focus on those with HIV in Colombia. Methods: This retrospective study was conducted in fourteen Health institutions in Colombia based on computerized clinical records from Jan 2022 to Dec 2023. Clinical and epidemiological characteristics were collected from diagnosis until discharge (or death). Participants in the study were diagnosed through molecular methods (PCR) and their clinical evolution was tracked through hospital and/or outpatient medical records. Registered variables were based on the mpox 2023 Case Report Form (2023 - CRF) proposed by the World Health Organization. Results: One thousand four hundred thirteen (1413, 97.2 % male) individuals, including 2.6 % identified as healthcare workers, were included in this study. The majority (54 %, 764/1413 individuals) were persons living with HIV (PWH) and almost one-third of them (30.1 %, n = 284) of participants had concomitant sexually transmitted diseases and HIV, with syphilis being the most prevalent (20.4 %), followed by Neisseria gonorrhoeae (16.4 %). Complications were infrequent, with cellulitis being the most common, and no individuals received mpox-specific treatment or vaccination. Although all individuals had skin lesions distributed across various body regions, differences were noted in lesion distribution among women. Those living with HIV showed higher emergency department attendance and reported having known mpox contacts. While complications were rare, with cellulitis being the most common, women living with HIV showed a higher rate of emergency room visits and known mpox contacts. Although not statistically significant, gastrointestinal, musculoskeletal, psychological, respiratory, and STI symptoms, including syphilis and urethritis, were more common in the virologically non-suppressed HIV group. At the same time, proctitis was more prevalent in the suppressed group. No significant differences were found based on CD4 count, using 200 cells/mm3 in PWH. Conclusion: Over half of the participants were people living with HIV (PWH), with a significant presence of STIs like syphilis. While skin lesions and complications varied, no significant differences were linked to CD4 count or viral load suppression. Mpox symptomatology was not significantly associated with unsuppressed viral loads or low CD4 levels, highlighting the need for further research.
KW - Colombia
KW - Complications
KW - HIV
KW - Monkeypox
KW - Mpox
KW - Outbreak
UR - https://www.scopus.com/pages/publications/105001716781
U2 - 10.1016/j.gloepi.2025.100197
DO - 10.1016/j.gloepi.2025.100197
M3 - Article
C2 - 40242136
AN - SCOPUS:105001716781
SN - 2590-1133
VL - 9
SP - 100197
JO - Global Epidemiology
JF - Global Epidemiology
M1 - 100197
ER -